TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04805502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Modes
Description: Moderate intensity aerobic exercise, moderate intensity resistance exercise, moderate intensity combination exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Modes
Description: Moderate intensity aerobic exercise, moderate intensity resistance exercise, moderate intensity combination exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Modes
Description: Moderate intensity aerobic exercise, moderate intensity resistance exercise, moderate intensity combination exercise
Study: NCT06159621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1inhibitor - LVGN 3616
Description: Administration of one dose of LVGN 3616 - 300mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1inhibitor - LVGN 3616
Description: Administration of one dose of LVGN 3616 - 300mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CD 40 Agonist - LVGN 7409
Description: Administration of one dose of LVGN 7409 - 1mg/kg
Study: NCT06204068

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spica cast
Description: Spica cast is a cast that is placed while the child is sedated or under anesthesia, covering lower part of belly, waist, and both legs made up of fiberglass, also keeps legs in abduction and flexion. This device will be used as intended and is commonly used for the treatment of DDH.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spica cast
Description: Spica cast is a cast that is placed while the child is sedated or under anesthesia, covering lower part of belly, waist, and both legs made up of fiberglass, also keeps legs in abduction and flexion. This device will be used as intended and is commonly used for the treatment of DDH.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhino brace
Description: Hip abduction brace will be used, which keeps the legs abducted and flexed. A hip brace is a special type of brace that is designed to hold the hips in a flexed and abducted position. This position allows the hip joint to develop properly while it heals. This device will be used as intended and is commonly used for the treatment of DDH.
Study: NCT04687306

Intervention type: DIAGNOSTIC_TEST
Intervention: X-rays- total of 4
Description: X-rays of the sacral scope, pelvic femoral angle and cup ante-inclination in both sitting and standing positions

Intervention type: DIAGNOSTIC_TEST
Intervention: X-rays- total of 4
Description: X-rays of the sacral scope, pelvic femoral angle and cup ante-inclination in both sitting and standing positions
Study: NCT05009498

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 supplementation
Description: Vitamin D3 in 50,000 IU capsules Loading dose of 150,000 IUs (3 capsules) Interval dosing of 50,000 IUs (1 capsule) every 2 weeks for 1 year

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, identical in appearance to the Vitamin D3 supplement capsule Dosing intervals identical in duration and quantity as Vitamin D3 supplement group
Study: NCT05535894

Intervention type: PROCEDURE
Intervention: Ablation of Celiac Ganglion
Description: Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion
Study: NCT04738786

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers
Description: Surgical resection including 1.5 cm normal tissue around the gross tumors~Definition of safety margin: A surgical safety margin is defined as the margin of apparently non-tumorous tissue around a tumor that has been surgically removed (Resected normal-looking tissues from the gross tumor border). The surgical safety margin is applied to all directions of 3-dimensional tumors (mucosal and deep side).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers
Description: Surgical resection including 1.0 cm normal tissue around the gross tumors
Study: NCT05690841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Focal Mass Drug Administration (fMDA)
Description: Administration of focal mass drug administration for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household). Intervention to be administered two times, two months apart each cycle, for 3 cycles spaced apart by 9-11 month intervals.~Each year will include 2 rounds of fMDA.~Round 1) Chloroquine (CQ)+ Tafenoquine (TQ) for \>= 16y (CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg CQ, TQ 300 mg on Day 1); CQ+ Primaquine (PQ) for \<16y (CQ: age-based dosing, PQ age-based dosing); CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg, PQ age-based dosing).~Round 2) single dose CQ+TQ for \>= 16y (CQ: Day1 600 mg, TQ 300 mg on Day 1); single dose CQ+PQ for \<16y (CQ: age-based dosing, PQ age-based dosing); single dose CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, PQ age-based dosing).
Study: NCT05615818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: Dose 20 mg once a day (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Dose 500 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Dose: Patients \< 70 kg: 1800 mg every 3 weeks (Q3W), Patients ≥ 70 kg: 2400 mg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Loading dose 8 mg/kg, then 6 mg/kg Q3W (Combination with neratinib)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Dose: 240 mg QD (combination with trastuzumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Dose: 450 mg QD (Combination with binimetinib)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Dose: 45 mg twice a day (BID) (Combination with encorafenib)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Dose: 200 mg QD or 300 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Dose: 25 mg/m2 IV on days 1 and 8 Q3W (CISGEM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Dose: 1000 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
Study: NCT06136169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder-cue scanning training
Description: Auditory reminders to scan when scanning to the side of the field loss is inadequate
Study: NCT06478667

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levosemindan
Description: inotropic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levosemindan
Description: inotropic agent
Study: NCT06338774

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Computerized cognitive training completed on any computer or tablet with internet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Computerized cognitive training completed on any computer or tablet with internet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Computerized cognitive training completed on any computer or tablet with internet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Aerobic exercise intervention with structured exercise sessions prescribed by a study exercise specialist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise intervention with structured exercise sessions prescribed by a study exercise specialist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise intervention with structured exercise sessions prescribed by a study exercise specialist
Study: NCT05161377

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical management
Description: Surgical clipping will be performed following randomization according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular management
Description: Endovascular treatment will also be performed following randomization, according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents, flow-diverters, ISFD/WEBs or other innovative devices, as well as post- treatment medical management issues, will be left up to the physician performing the endovascular treatment and initial strategies determined prior to randomization.
Study: NCT05025787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-6970
Description: CNTX-6970, a novel potent antagonist of CCR2 with lesser effects on CCR5, is being developed as a new treatment for chronic pain, including painful osteoarthritis of the knee.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID
Study: NCT06518954

Intervention type: OTHER
Intervention: Interview
Description: The athletes contributes with experience exchange through individual interviews, following a interview template

Intervention type: OTHER
Intervention: Interview
Description: The athletes contributes with experience exchange through individual interviews, following a interview template
Study: NCT06006208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hamilton C1 ventilator during transport to the ICU
Description: Instead of AMBU bag manual ventilation during transport to the ICU, intervention is using Hamilton C1 ventilator during transport to the ICU
Study: NCT06220032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Day 1 Cycle 1-6: Dexrazoxane 500 mg/m2 (iv) will be given 30 minutes before doxorubicin infusion and should be infused during 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Day 1 Cycle 1-6: 375 mg/m2 (iv)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Day 1 Cycle 1-6: 375 mg/m2 (iv)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day 1 Cycle 1-6: 750 mg/m2 (iv)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day 1 Cycle 1-6: 750 mg/m2 (iv)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Day 1 Cycle 1-6: 50 mg/m2 (iv)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Day 1 Cycle 1-6: 50 mg/m2 (iv)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Day 1 Cycle 1-6: 1.4 mg/m2 (max 2 mg) (iv)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Day 1 Cycle 1-6: 1.4 mg/m2 (max 2 mg) (iv)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Day 1-5 Cycle 1-6: 100 mg (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Day 1-5 Cycle 1-6: 100 mg (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Day 1-14 Cycle 1-6: 15 mg day (oral) Only in case of a double hit lymphoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Day 1-14 Cycle 1-6: 15 mg day (oral) Only in case of a double hit lymphoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg (1 dose per cycle) in case of neutropenia. Pegfilgastim is mandatory in patients that receive R2-CHOP21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg (1 dose per cycle) in case of neutropenia. Pegfilgastim is mandatory in patients that receive R2-CHOP21.
Study: NCT06202365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body Vibration
Description: A vibrating platform (WBV) will be used in this study with 6 training exercises for 4 minutes, 2 times /week for 6 weeks. Feet should be parallel at shoulder width apart and knees hold constant. WBV sessions were conducted from low to medium-vibration mode

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Whole body vibration
Description: They will receive the same intervention while the device turned off for 4 minutes, 2 times /week for 6 weeks.
Study: NCT05273567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guanfacine-ER
Description: guanfacine-er dispensed daily, starting at 1mg and increasing to 4mg/day or the maximum tolerated dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo will be dispensed similar to the active arm.
Study: NCT05017415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uroflow measurement
Description: Non-invasive urodynamic measurement wireless uroflowmeter UROCAP™ IV, Goby System Laborie

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uroflow measurement
Description: Non-invasive urodynamic measurement wireless uroflowmeter UROCAP™ IV, Goby System Laborie

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bladder ultrasound
Description: Ultrasound of post void residual urine bladderscan CUBEscan BioCon 700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bladder ultrasound
Description: Ultrasound of post void residual urine bladderscan CUBEscan BioCon 700
Study: NCT06602518

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic Treatment
Description: All the enrolled patients will undergo conventional fixed appliance therapy by bonding straight wire Roth appliance in the maxillary arch. The bonding procedure will be standardized in all patients and performed by the same operator using light-cured composite. Levelling and alignment will then be started using the following wire sequence: 0.014-in nickel titanium (NiTi), 0.018-in NiTi, 17×25-in Niti, and 19×25-in Niti arch wires. The upper arch will then be stabilized using a 19×25-in stainless steel (SS) arch wire for 2 months. This stage will require approximately 6 months of treatment.
Study: NCT06706037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A 6 week reformer pilates exercise program
Study: NCT06705556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active cycle of breathing technique, incentive spirometer, percussion, 3-minute of walking
Description: The intervention group:~patients were asked to perform Active cycle of breathing technique as add on to routine chest physical therapy such as Incentive spirometer, percussion, 3-minute of walking 3 days before surgery and five days postoperative.~* Incentive spirometry, 3 sessions per day, 10 repetitions~* Percussions, 3 sessions per day, 20 repetitions~* 3-minutes walking, 2 sessions per day~* ACBT, 3 sessions per day the following were included postoperatively:~* Nebulization, 3 sessions per day~* ACBT, 3 sessions per day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: incentive spirometer, percussion, 3-minute of walking
Description: The control group The routine CPT was performed 3 days before surgery at the preoperative bay and 5 days after surgery in the ICU with 3 sessions each day.~Preoperative chest physical therapy sessions were followed as:~* Incentive spirometry, 3 sessions per day, 10 repetitions.~* Percussions, 3 sessions per day, 20 repetitions.~* 3-minutes walking, 2 sessions per day The preoperative chest physiotherapy treatment plan was continued after CABG surgery. In addition to these, the following were included postoperatively:~* Nebulization, 3 sessions per day~* 3-minutes walking, 2 sessions per day
Study: NCT06704425

Intervention type: OTHER
Intervention: For observational studies, participants are not assigned an intervention as part of the study.
Description: For observational studies, participants are not assigned an intervention as part of the study.

Intervention type: OTHER
Intervention: For observational studies, participants are not assigned an intervention as part of the study.
Description: For observational studies, participants are not assigned an intervention as part of the study.
Study: NCT06705231

Intervention type: BEHAVIORAL
Intervention: The Aarhus-intervention
Description: A multifactorial family-centered lifestyle intervention with a maximum duration of one year, corresponding to three-four visits. Participants were offered complimentary weekly supervised physical activity. The day-to-day intervention was managed by specialized nurses at local healthcare centers, at the participants' homes, or in a local clinic.

Intervention type: BEHAVIORAL
Intervention: The Aarhus-intervention
Description: A multifactorial family-centered lifestyle intervention with a maximum duration of one year, corresponding to three-four visits. Participants were offered complimentary weekly supervised physical activity. The day-to-day intervention was managed by specialized nurses at local healthcare centers, at the participants' homes, or in a local clinic.
Study: NCT06551051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: Patients were treated with duloxetine at a recommended dose of 40mg/day, increasing to a maximum dose of 60mg/day after seven days of non-significant discomfort.
Study: NCT05757713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: teplizumab
Description: CD3-directed humanized monoclonal antibody
Study: NCT04965142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: The intervention group will be asked to complete aerobic exercises 3 to 5 times per week (≥ 150 minutes of at least moderate aerobic intensity) and resistance training at least twice a week over a 12-week period.
Study: NCT04861129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bowen therapy
Description: Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Bowen therapy
Description: Sham Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
Study: NCT05177510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Progestin Antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04822675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous mitral valve repair
Description: Percutaneous mitral repair will be performed using the MitraClip system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical mitral valve repair/replacement
Description: All mitral valve surgeries will be performed either via sternotomy or right thoracotomy, and with cardioplegic arrest and cardiopulmonary bypass. Mitral valve repair may include annuloplasty and adjunctive procedures as determined by the operating surgeon. For mitral valve replacement, the choice of mitral valve prosthesis will be left at the surgeon's discretion.
Study: NCT06305156

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Bone Mineral Density quantification
Description: In the first visit, participants receive clinically indicated CT scan, where bone mineral density will be derived.~In a second, study related visit, participants will receive a DXA scan for bone mineral quantifications.
Study: NCT05866666

Intervention type: DEVICE
Intervention: Cardiac Performance System (NSR)
Description: Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function.
Study: NCT06071845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge Procedure
Description: Investigators will follow the Cytosponge Cell Collection Kit Instructions for Use to administer and retrieve the Cytosponge device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cytosponge Procedure
Description: Investigators will follow the Cytosponge Cell Collection Kit Instructions for Use to administer and retrieve the Cytosponge device.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopic Assessment
Description: Participants will undergo a diagnostic clinically indicated sedated endoscopy with standard endoscopic equipment.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Assessment
Description: Participants will undergo a diagnostic clinically indicated sedated endoscopy with standard endoscopic equipment.
Study: NCT05834439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flower printing activities for the elderly
Description: Experimental group

Intervention type: OTHER
Group type: OTHER
Intervention: Routine activities in nursing home
Description: Control group
Study: NCT05356234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Intervention: Responsible Parenting, Relationships, and Employment Services
Description: The Intervention group will be assigned a Case Manager and placed in the next available On My Shoulders (OMS) curriculum that offers strategies to help individuals develop a strong and healthy self in the service of making current and/or future relationships of all forms (parent-child, romantic, family, work) successful and satisfying. This curriculum is intended to equip men (and, where applicable, women) with the skills they need to build and nurture healthy relationships. This curriculum should help participants improve family functioning. Additionally, Transforming Impossible into Possible (TIP) financial literacy curriculum will be utilized to help participants increase job retention for those currently employed, improve wages through additional educational and training opportunities, and learn skills to better manage family finances. This curriculum should help participants increase economic stability and mobility.
Study: NCT06196736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2821
Description: 1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: 75mg/m\^2 docetaxel by intravenous infusion or 175 mg/m\^2 paclitaxel by intravenous infusion on day 1 of every 21-day cycle.